Trial Profile
Prospective, Observational, 12-month Assessment of Canagliflozin Treatment in Type 2 Diabetes Mellitus in a Usual Clinical Practice in Canada (CANadian CAnagliflozin REgistry: CanCARE)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Canagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms CanCARE
- Sponsors Janssen Inc
- 05 Oct 2018 12-month results presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
- 26 Jun 2018 Results (n=527) presented at the 78th Annual Scientific Sessions of the American Diabetes Association.
- 08 Jun 2018 According to the Janssen media release, data from this trial will be presented at the American Diabetes Association's 78th Annual Scientific Sessions 2018.